Featured Opinions
Several ways that pharma can harness the power of social media
by Clifford M
The debate, if you can call it that, over whether or not interactive social media platforms like Facebook and Twitter can be used in the life science industry is moving forward at glacial speed.
by Anonymous (not verified)
I suppose I can coin the turn MAMS, Manage Access Manage Success.
Pharma to rely less on internal R&D programs
by Clifford M
The drug maker Eli Lilly and Co quietly launched a new website today for a program dubbed Lilly Phenotypic Drug Discovery Initiative or PD2.
Looking to the East: GlaxoSmithKline inks a deal with Indias Dr. Reddys Laboratories
by Clifford M
GlaxoSmithKline (GSK) inked a deal yesterday with the Indian generics manufacturer Dr.
Can pharmacists pick up the slack?
There has been a lot of talk in this blog stream about how to encourage patients to regularly take their medication and 'comply' with doctors orders.
More doctors disagreeing with AMA over universal care
by Alison Bass
As Congress steps up its efforts to craft a comprehensive health care reform bill, Senator Edward Kennedy (in absentia) is leading the charge for a public health insurance option that can compete with
Pharma Marketing - Is it time for a name change?
Marketers in the Pharmaceutical industry have always perceived themselves to be different, given the specialist market they work in.
Compliance - finding the forest amid the trees
by Anonymous (not verified)
The fragmentation of our stakeholders has given us many things, one of which is Key Account Management. Is this another fad? Do we know what we are talking about?
In an instances of serendipity, the AMA and I have each been independently engaged in changing the current perspective and policies on management of non-compliant patients.
Job Opportunities for Indian Life Scientists
by Clifford M
As many of you may know, I attend national science meetings where I offer resume critiquing services and give career development seminars on topics ranging from resume writing to alternate career oppo
Cosmetic Surgery: A New Way to Retain Nurses and Other Hospital Employees?
by Clifford M
There is a growing worldwide shortage of nurses and other typically female-dominated medical professionals.
Follow-on Biologics Debate in the US: Innovator Companies Lose Round 2
by Clifford M
A much-anticipated Federal Trade Commission (FTC) report was released on Wednesday that will likely help House Energy and Commerce Chairman Henry Waxman bolster support for his fledgling follow-on bio
Ten Digital Marketing Ideas Pharma Companies Will Never Try (But Should)
I figure this post is the one that'll get the most comments ever. It's going to be the one that probably outrages you the most or makes you think that I've completely lost it (which perhaps I have).
Patient Compliance - so wrong for so long
The journey to an alternative to the current concept of compliance proceeds through the slough of despond where the flawed status quo is lamented, but the prospect of what could be is sighted.
by cadelarge
I am reposting, with permission, a synopsis of this compelling meeting of the Digerati written by my good colleague Christine Szymanski, Sr. Manager, Patient Relationship Marketing, Novo Nordisk, US.
by Anonymous (not verified)
The fish rots from the head: conflicts of interest at Partners and Harvard Medical School
by Alison Bass
Much has been written about prominent doctors who fail to disclose their lucrative financial ties with pharmaceutical and medical device companies.
Ethical dilemma - any lessons from the UK MP's expenses fiasco
The UK political system has gone into melt down in recent weeks. If only they knew the full impact of freedom of information.
by Anonymous (not verified)
Like almost everyone else in pharma - and beyond, we here at eyeforpharma are intrigued and excited by the promise of new social media tools like Twitter and Facebook and their potential value to pharma marketers.
Using Digital to Address the Needs of Caregivers
As pharma and healthcare companies become more sophisticated with their digital offerings, it starts to become much simpler to provide individualized content.
by Anonymous (not verified)
What do clinical trials and patient-level data have in common?